litlas
Log inCreate account

Christopher R. Vakoc

Active 2005–2025

102
Papers
23,953
Citations
65
h-index
96
i10-index

Citations

Citations per year for Christopher R. Vakoc1993: 1 citations1996: 2 citations2003: 1 citations2005: 12 citations2006: 59 citations2007: 71 citations2008: 90 citations2009: 92 citations2010: 102 citations2011: 113 citations2012: 209 citations2013: 220 citations2014: 333 citations2015: 354 citations2016: 370 citations2017: 400 citations2018: 408 citations2019: 1,202 citations2020: 1,357 citations2021: 1,562 citations2022: 1,132 citations2023: 845 citations2024: 1,306 citations2025: 656 citations2026: 17 citations1994–1995: no citations, so these years are not shown1997–2002: no citations, so these years are not shown2004: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,305 citing papers, 33.2% of this breakdownChina: 2,066 citing papers, 15.9% of this breakdownUnited Kingdom: 829 citing papers, 6.4% of this breakdownGermany: 770 citing papers, 5.9% of this breakdownItaly: 438 citing papers, 3.4% of this breakdownJapan: 400 citing papers, 3.1% of this breakdownFrance: 396 citing papers, 3.1% of this breakdownCanada: 379 citing papers, 2.9% of this breakdownNetherlands: 316 citing papers, 2.4% of this breakdownAustralia: 287 citing papers, 2.2% of this breakdownSpain: 285 citing papers, 2.2% of this breakdownSwitzerland: 239 citing papers, 1.8% of this breakdown
0%33.2%Other 17.5%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology64.8%
  • Medicine29.4%
  • Immunology and Microbiology2.6%
  • Engineering0.9%
  • Neuroscience0.6%
  • Agricultural and Biological Sciences0.5%
  • Other1.2%

Topics

  • Protein Degradation and Inhibitors8%
  • Epigenetics and DNA Methylation6.2%
  • Genomics and Chromatin Dynamics4.9%
  • RNA modifications and cancer4.9%
  • Cancer-related gene regulation4%
  • Ubiquitin and proteasome pathways3.9%
  • Other68.1%

Coauthors

All papers

Open in search
  1. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

    Authors: Charles M. Rudin, John T. Poirier, Lauren A. Byers, Caroline Dive, Afshin Dowlati, Julie George, John V. Heymach, Jane E. Johnson, Jonathan M. Lehman, David MacPherson, Pierre P. Massion, John D. Minna, Trudy G. Oliver, Vito Quaranta, Julien Sage, Roman K. Thomas, Christopher R. Vakoc, Adi F. Gazdar - Nature reviews. Cancer 2019 cited by 1,275

  2. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

    Authors: Hervé Tiriac, Pascal Belleau, Dannielle D. Engle, Dennis Plenker, Astrid Deschênes, Tim D.D. Somerville, Fieke E. M. Froeling, Richard A. Burkhart, Robert E. Denroche, Gun-Ho Jang, Koji Miyabayashi, C. Megan Young, Hardik J. Patel, Michelle Ma, Joseph F. LaComb, Randze Lerie D. Palmaira, Ammar A. Javed, Jasmine C. Huynh, Molly Johnson, Kanika Arora, Nicolas Robine, Minita Shah, Rashesh Sanghvi, Austin Goetz, Cinthya Y. Lowder, Laura Martello, Else Driehuis, Nicolas Lecomte, Gökçe Aşkan, Christine A. Iacobuzio–Donahue, Hans Clevers, Laura D. Wood, Ralph H. Hruban, Elizabeth D. Thompson, Andrew J. Aguirre, Brian M. Wolpin, Aaron R. Sasson, Joseph Kim, Maoxin Wu, Juan Carlos Bucobo, Peter J. Allen, Divyesh V. Sejpal, William H. Nealon, J. D. Sullivan, Jordan M. Winter, Phyllis A. Gimotty, Jean L. Grem, Dominick J. DiMaio, Jonathan M. Buscaglia, Paul M. Grandgenett, Jonathan R. Brody, Michael A. Hollingsworth, Grainne M. O’Kane, Faiyaz Notta, Edward Kim, James M. Crawford, Craig Devoe, Allyson J. Ocean, Christopher L. Wolfgang, Kenneth H. Yu, Ellen Li, Christopher R. Vakoc, Benjamin Hubert, Sandra E. Fischer, Julie M. Wilson, Richard A. Moffitt, Jennifer J. Knox, Alexander Krasnitz, Steven Gallinger, David A. Tuveson - Cancer Discovery 2018 cited by 1,094

  3. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

    Authors: Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux, Peter B. Rahl, Junwei Shi, Hannah M. Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M. Paranal, Jun Qi, Marta Chesi, Anna C. Schinzel, Michael R. McKeown, Timothy P. Heffernan, Christopher R. Vakoc, P. Leif Bergsagel, Irene M. Ghobrial, Paul G. Richardson, Richard A. Young, William C. Hahn, Kenneth C. Anderson, Andrew L. Kung, James E. Bradner, Constantine S. Mitsiades - Cell 2011 cited by 2,874

  4. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control

    Authors: Isaia Barbieri, Konstantinos Tzelepis, Luca Pandolfini, Junwei Shi, Gonzalo Millán-Zambrano, Samuel C. Robson, Demetrios Aspris, Valentina Migliori, Andrew J. Bannister, Namshik Han, Étienne De Braekeleer, Hannes Ponstingl, Alan G. Hendrick, Christopher R. Vakoc, George S. Vassiliou, Tony Kouzarides - Nature 2017 cited by 1,148

  5. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment

    Authors: Xue‐Yan He, Yuan Gao, David Ng, Evdokia Michalopoulou, Shanu George, José M. Adrover, Lijuan Sun, Jean Albrengues, Juliane Daßler‐Plenker, Xiao Han, Ledong Wan, Xiaoli Wu, Longling S. Shui, Yuhan Huang, Bodu Liu, Chang Su, David L. Spector, Christopher R. Vakoc, Linda Van Aelst, Mikala Egeblad - Cancer Cell 2024 cited by 248

  6. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

    Authors: Johannes Zuber, Junwei Shi, Eric Wang, Amy Rappaport, Harald Herrmann, Edward Allan R. Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich, Meredith J. Taylor, Christopher Johns, Agustin Chicas, James C. Mulloy, Scott C. Kogan, Patrick A. Brown, Peter Valent, James E. Bradner, Scott W. Lowe, Christopher R. Vakoc - Nature 2011 cited by 1,884

  7. BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance

    Authors: Nilgun Tasdemir, Ana Banito, Jae‐Seok Roe, Direna Alonso‐Curbelo, Matthew Camiolo, Darjus F. Tschaharganeh, Chun‐Hao Huang, Ozlem Aksoy, Jessica E. Bolden, Chi-Chao Chen, Myles Fennell, Vishal Thapar, Agustin Chicas, Christopher R. Vakoc, Scott W. Lowe - Cancer Discovery 2016 cited by 404

  8. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

    Authors: Yuhan Huang, Olaf Klingbeil, Xue‐Yan He, Xiaoli Wu, Gayatri Arun, Bin Lu, Tim D.D. Somerville, Joseph P. Milazzo, John E. Wilkinson, Osama E. Demerdash, David L. Spector, Mikala Egeblad, Junwei Shi, Christopher R. Vakoc - Genes & Development 2018 cited by 427

  9. The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition

    Authors: Junwei Shi, Christopher R. Vakoc - Molecular Cell 2014 cited by 893

  10. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis

    Authors: Jae‐Seok Roe, Chang‐Il Hwang, Tim D.D. Somerville, Joseph P. Milazzo, Eun Jung Lee, Brandon Da Silva, Laura Maiorino, Hervé Tiriac, C. Megan Young, Koji Miyabayashi, Dea Filippini, Brianna Creighton, Richard A. Burkhart, Jonathan M. Buscaglia, Edward Kim, Jean L. Grem, Audrey J. Lazenby, James A. Grunkemeyer, Michael A. Hollingsworth, Paul M. Grandgenett, Mikala Egeblad, Youngkyu Park, David A. Tuveson, Christopher R. Vakoc - Cell 2017 cited by 496

  11. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains

    Authors: Junwei Shi, Eric Wang, Joseph P. Milazzo, Zihua Wang, Justin B. Kinney, Christopher R. Vakoc - Nature Biotechnology 2015 cited by 787

  12. Optimized base editors enable efficient editing in cells, organoids and mice

    Authors: María Paz Zafra, Emma M. Schatoff, Alyna Katti, Miguel Foronda, Marco Breinig, Anabel Y. Schweitzer, Amber Simon, Teng Han, Sukanya Goswami, Emma Montgomery, Jordana K. Thibado, Edward R. Kastenhuber, Francisco J. Sánchez‐Rivera, Junwei Shi, Christopher R. Vakoc, Scott W. Lowe, Darjus F. Tschaharganeh, Lukas E. Dow - Nature Biotechnology 2018 cited by 351

  13. OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage

    Authors: Xiaoli Wu, Xue‐Yan He, Jonathan J. Ipsaro, Yuhan Huang, Jonathan Preall, David Ng, Yan Ting Shue, Julien Sage, Mikala Egeblad, Leemor Joshua‐Tor, Christopher R. Vakoc - Nature 2022 cited by 95

  14. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

    Authors: Gerard L. Brien, David Remillard, Junwei Shi, Matthew L. Hemming, Jonathon Chabon, Kieran Wynne, Eugène Dillon, Gerard Cagney, Guido van Mierlo, Marijke Baltissen, Michiel Vermeulen, Jun Qi, Stefan Fröhling, Nathanael S. Gray, James E. Bradner, Christopher R. Vakoc, Scott A. Armstrong - eLife 2018 cited by 216

  15. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

    Authors: Philipp Rathert, Mareike Roth, Tobias Neumann, Felix Muerdter, Jae‐Seok Roe, Matthias Muhar, Sumit Deswal, Sabine Cerny‐Reiterer, Barbara Peter, Julian Jude, Thomas Hoffmann, Łukasz M. Boryń, Elin Axelsson, Norbert Schweifer, Ulrike Tontsch-Grunt, Lukas E. Dow, Davide Gianni, Mark Pearson, Peter Valent, Alexander Stark, Norbert Kraut, Christopher R. Vakoc, Johannes Zuber - Nature 2015 cited by 522

  16. BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network

    Authors: Xueqin Sherine Sun, Olaf Klingbeil, Bin Lü, Caizhi Wu, Carlos Ballon, Meng Ouyang, Xiaoli Wu, Ying Jin, Yon Hwangbo, Yuhan Huang, Tim D.D. Somerville, Kenneth Chang, Jung Woo Park, Taemoon Chung, Scott K. Lyons, Junwei Shi, Hannes Vogel, Michael Schulder, Christopher R. Vakoc, Alea A. Mills - Nature 2022 cited by 81

  17. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma

    Authors: Tim D.D. Somerville, Yali Xu, Koji Miyabayashi, Hervé Tiriac, Cristian R. Cleary, Diogo Maia-Silva, Joseph P. Milazzo, David A. Tuveson, Christopher R. Vakoc - Cell Reports 2018 cited by 234

  18. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

    Authors: Warren Fiskus, Christopher P. Mill, Christine Birdwell, John A. Davis, Kaberi Das, Steffen Boettcher, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Sanam Loghavi, Michael Soth, Tim Heffernan, Gerard M. McGeehan, Xinjia Ruan, Xiaoping Su, Christopher R. Vakoc, Naval Daver, Kapil N. Bhalla - Blood Cancer Journal 2023 cited by 54

  19. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

    Authors: Laetitia J. Martin, Manfred Koegl, Gerd Bader, Xiaoling Cockcroft, O. Fedorov, Dennis Fiegen, Thomas Gerstberger, Marco H. Hofmann, Anja Hohmann, Dirk Kessler, Stefan Knapp, Petr Knesl, Stefan Kornigg, Susanne Müller, Herbert Nar, Catherine Rogers, Klaus Rumpel, Otmar Schaaf, Steffen Steurer, C. Tallant, Christopher R. Vakoc, Markus Zeeb, Andreas Zoephel, Mark Pearson, Guido Boehmelt, Darryl B. McConnell - Journal of Medicinal Chemistry 2016 cited by 224

  20. Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma

    Authors: Berkley E. Gryder, Silvia Pomella, Carly M. Sayers, Xiaoli Wu, Young Song, Anna M. Chiarella, Sukriti Bagchi, Hsien-Chao Chou, Ranuka Sinniah, Ashley Walton, Xinyu Wen, Rossella Rota, Nathaniel A. Hathaway, Keji Zhao, Jiji Chen, Christopher R. Vakoc, Jack F. Shern, Benjamin Z. Stanton, Javed Khan - Nature Genetics 2019 cited by 177

  21. New Approaches to SCLC Therapy: From the Laboratory to the Clinic

    Authors: John T. Poirier, Julie George, Taofeek K. Owonikoko, Anton Berns, Élisabeth Brambilla, Lauren A. Byers, David P. Carbone, Huanhuan Joyce Chen, Camilla L. Christensen, Caroline Dive, Anna F. Farago, Ramaswamy Govindan, Christine L. Hann, Matthew D. Hellmann, Leora Horn, Jane E. Johnson, Young Seok Ju, Sumin Kang, Mark A. Krasnow, James Lee, Se‐Hoon Lee, Jonathan M. Lehman, Benjamin H. Lok, Christine M. Lovly, David MacPherson, David G. McFadden, John D. Minna, Matthew G. Oser, Keunchil Park, Kwon-Sik Park, Yves Pommier, Vito Quaranta, Neal Ready, Julien Sage, Giorgio V. Scagliotti, Martin L. Sos, Kate D. Sutherland, William D. Travis, Christopher R. Vakoc, Sarah J. Wait, Ignacio I. Wistuba, Kwok‐Kin Wong, Hua Zhang, Jillian B. Daigneault, Jacinta Wiens, Charles M. Rudin, Trudy G. Oliver - Journal of Thoracic Oncology 2020 cited by 176

  22. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation

    Authors: Junwei Shi, Warren A. Whyte, Cinthya Zepeda‐Mendoza, Joseph P. Milazzo, Chen Shen, Jae‐Seok Roe, Jessica L. Minder, Fatih Mercan, Eric Wang, Mélanie Eckersley-Maslin, Amy E. Campbell, Shinpei Kawaoka, Sarah J. Shareef, Zhu Zhu, Jude Kendall, Matthias Muhar, Christian Haslinger, Ming Yu, Robert G. Roeder, Michael Wigler, Gerd A. Blobel, Johannes Zuber, David L. Spector, Richard A. Young, Christopher R. Vakoc - Genes & Development 2013 cited by 458

  23. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes

    Authors: Koji Miyabayashi, Lindsey A. Baker, Astrid Deschênes, Benno Traub, Giuseppina Caligiuri, Dennis Plenker, Brinda Alagesan, Pascal Belleau, Siran Li, Jude Kendall, Gun Ho Jang, Risa Karakida Kawaguchi, Tim D.D. Somerville, Hervé Tiriac, Chang‐Il Hwang, Richard A. Burkhart, Nicholas J. Roberts, Laura D. Wood, Ralph H. Hruban, Jesse Gillis, Alexander Krasnitz, Christopher R. Vakoc, Michael Wigler, Faiyaz Notta, Steven Gallinger, Youngkyu Park, David A. Tuveson - Cancer Discovery 2020 cited by 130

  24. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia

    Authors: Charles C. Bell, Katie Fennell, Yih-Chih Chan, Florian Rambow, Miriam M. Yeung, Dane Vassiliadis, Luis E. Lara Gonzalez, Paul Yeh, Luciano G. Martelotto, Aljosja Rogiers, Brandon E. Kremer, Olena Barbash, Helai P. Mohammad, Timothy M. Johanson, Marian L. Burr, Arindam Dhar, Natalie O. Karpinich, Luyi Tian, Dean Tyler, Laura MacPherson, Junwei Shi, Nathan Pinnawala, Chun Yew Fong, Anthony T. Papenfuss, Sean M. Grimmond, Sarah‐Jane Dawson, Rhys S. Allan, Ryan G. Kruger, Christopher R. Vakoc, David L. Goode, Shalin H. Naik, Omer Gilan, Enid Y.N. Lam, Jean‐Christophe Marine, Rab K. Prinjha, Mark A. Dawson - Nature Communications 2019 cited by 180